Form 4: ALX Oncology President and CSO Jaume Pons Sells Shares to Cover Tax Obligations

Jaume Pons, President and CSO of ALX Oncology Holdings Inc., sold 10,796 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Jaume Pons, the President and CSO of ALX Oncology Holdings Inc., sold 10,796 shares of common stock on December 30, 2024.
• The sale was executed to satisfy tax obligations arising from the vesting of restricted stock units.
• The shares were sold at a weighted average price of $1.5802 per share.
• The transactions occurred at prices ranging from $1.58 to $1.60 per share.
• Following the transaction, Mr. Pons beneficially owns 580,714 shares of ALX Oncology stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment towards the company's prospects.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the biotechnology industry.
• Many executives at comparable companies such as Iovance Biotherapeutics and Legend Biotech also regularly file Form 4s for similar transactions.
• The volume of shares sold is relatively small compared to the total shares outstanding, which is typical for these types of transactions.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is generally not considered a significant event.

Key Dates

Keywords

ALX Oncology, Jaume Pons, stock sale, insider trading, Form 4, restricted stock units, tax obligations